Tavexia Lifecare Explores 60% Stake Acquisition in Meyonex Pharmaceuticals and Appoints Auditor
Sattva Sukun Lifecare Ltd · Others (Uncategorized) · 08 Sept 2026, 12:58 am
Tavexia Lifecare Explores 60% Stake Acquisition in Meyonex Pharmaceuticals and Appoints Auditor Tavexia Lifecare's board approved evaluating an acquisition of up to a 60% equity stake in unlisted Meyonex Pharmaceuticals (paid-up capital of ₹13.998 crore), authorizing directors to conduct due diligence, valuations, and negotiations. Effective 7th Sep'26, the board accepted the resignation of statutory auditor M/s SSRV & Associates and approved appointing M/s DEVAM & Associates LLP for a five-year term (FY27 to FY31), pending shareholder approval. Additionally, the board approved the re-appointment of Independent Director Khushboo Vasudev for a second five-year term starting 31st Dec'26.
Original exchange filing (PDF)
More announcements from Sattva Sukun Lifecare Ltd
- Financial Result · 05 Nov 2026
- Announcement · 05 Nov 2026
- Board has Approved in Change in RTA · 05 Nov 2026
- Result · 05 Nov 2026
- Outcome of Board Meeting · 05 Nov 2026
- Tavexia Lifecare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Intimation of Board Meeting · 04 Nov 2026
- Announcement · 13 Oct 2026
- Disclosure under regulation 30 · 12 Oct 2026
